An integral part of the annual meeting of the American Society of Retina Specialists (ASRS), and any retina meeting, has always been walking the exhibit hall floor to check out the new products and technologies that are available to help us improve patient care and practice. Retinal Physician has invited leading vendors to provide information and insight on their new product offerings. In this Product Pavilion offering, you will find a display of the latest technologies that companies have recently brought to market. A link is included for a deeper dive into these companies and product features. You will also be receiving an email of this Product Pavilion feature with direct links to these vendor and product websites.
I am always amazed at the innovation and breakthroughs taking place in our field. Patient care usually begins with technology, and the following products are here to do just that — to help improve your patient outcomes and practice success. Thank you to our product vendors!
Peter K. Kaiser, MD
Editor in Chief
ALCON
As the global leader in surgical retina, Alcon represents not only quality and continuous improvement, but also an indispensable partner providing breakthrough technologies that can help you improve your patient outcomes and your practice. Perform the way you want today. Learn more about the latest from Alcon by visiting the booth at ASRS.
APELLIS
Apellis is a global biopharmaceutical company that leverages courageous science, creativity, and compassion to lead the development of therapies that target the complement system. Apellis is committed to addressing the unmet medical needs of patients and eye care professionals worldwide, with the goal of slowing progression of geographic atrophy.
DORC
TissueBlue, a 0.025% brilliant blue G ophthalmic solution, is the first FDA-approved dye designed to aid in ophthalmic surgery by selectively staining the internal limiting membrane. As an FDA-approved product, TissueBlue meets active pharmaceutical ingredient standards, assuring levels of purity and consistency in manufacture. Available in a prefilled sterile 0.5-mL syringe.
eSIGHT
eSight — See New Possibilities. Empower patients with eSight, the clinically validated, all-in-one solution for low-vision patients, proven to enhance vision. Extensive research and purpose-driven design sets eSight apart. From seeing faces, advancing in school or work, or resuming hobbies, eSight dramatically improves quality of life.
LEITERS
Leiters is an FDA-registered 503B outsourcing provider of quality compounded sterile preparations and pharmacy services. Leiters offers an FDA-compliant repackaged Avastin service as well as a variety of ready-to-use ophthalmic medications, including injections, antibiotics, dilating agents, and topical anesthetics for physicians and their patients.
OPTOS
Single-capture UWF retinal imaging with optomap is making eye care more efficient. A 2012 study documented a 33% (28-minute) reduction in patient visit duration after implementing centralized optomap imaging.1 Others show that optomap uncovers 42% more pathology2 and optomap-guided OCT imaging impacted clinical decision making in 84% of cases.3
- Lin et al; Retina; 2021.
- Chen et al; Ophthalmology Retina; 2020.
- Sodhi et al; International Ophthalmology; 2021.
SPARK THERAPEUTICS
Spark Therapeutics is a fully integrated commercial company committed to discovering, developing, and delivering gene therapies. Founded in 2013, Spark Therapeutics is the first company in the United States to receive FDA approval of a gene therapy for a genetic disease. Today, as a member of the Roche Group, Spark is focused on breaking barriers for people and families affected by genetic diseases, including blindness, hemophilia, lysosomal storage disorders, and neurodegenerative disease.
![]({"src":"/media/0akptgrg/cover_rp_0622.jpg","focalPoint":null,"crops":[{"alias":"thumbnail","width":1110,"height":700,"coordinates":null}]})